According to the latest research, AstraZeneca's new drug Truqap has not helped patients with a difficult-to-treat type of breast cancer to extend their lives. The pharmaceutical company said on Tuesday that in late-stage studies, scientists combined this drug with a common chemotherapy drug. Volunteers receiving treatment have triple negative breast cancer, one of the most challenging diseases that has spread and cannot be treated surgically. The trial showed that compared with the combined use of chemotherapy and placebo, the treatment plan did not reach the dual main endpoint of improving overall survival rate. AstraZeneca's potential anti-cancer drug Truqap has recently been approved in the USA and the EU for the treatment of other types of breast cancer.
阿斯利康新药Truqap联合化疗乳腺癌后期试验未达到主要目标
AstraZeneca's new drug Truqap combined with chemotherapy did not achieve the main goal in the late-stage trial of breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.